Altamira Therapeutics Prices $12M Public Offering with Warrants for Future Growth

Altamira Therapeutics (NASDAQ) has announced the pricing of a public offering involving 5.56 million common shares bundled with Series A-1 and Series A-2 common warrants at $0.72 per share. The company expects to raise $4 million initially. If investors fully exercise the accompanying warrants, Altamira could receive an additional $8 million, bringing the potential total to $12 million. This capital injection could support the company’s ongoing development and operational goals.